Original title: Intravascular Ultrasound-Guided Implantation of Drug-Eluting Stents to Improve Outcome. A Meta-Analysis. Reference: Jae-Sik Jang et al. J Am Coll Cardiol Intv 2014, epub ahead of print. Several previous studies and meta-analysis showed that implantation of conventional stents (BMS) intravascular ultrasound (IVUS) guided may decrease restenosis and clinical events. This information was not yet clear to drug-eluting<a href="https://solaci.org/en/2014/02/26/best-results-of-angioplasty-with-des-guided-by-ivus-versus-angiography-only/" title="Read more" >...</a>
The length of the stent is not an event predictor with the new generation of DES. It is the end of the Spot stenting?
Original title: Impact of the Stent Length on Long-Term Clinical Outcomes Following Newer-Generation Drug-Eluting Stent Implantation. Reference: Ik Jun Choi et al. Am J Cardiol 2014;113:457-464. Completely cover the lesion with a sufficiently long stent has been the preferred strategy that emerged from drug-eluting stents (DES). However, for the first-generation DES stent length has been a predictor of<a href="https://solaci.org/en/2014/02/20/the-length-of-the-stent-is-not-an-event-predictor-with-the-new-generation-of-des-it-is-the-end-of-the-spot-stenting/" title="Read more" >...</a>
Hybrid revascularization versus conventional surgery. Advantages and disadvantages for choosing ideal patients.
Original title: Clinical Outcomes after Hybrid Coronary Revascularization versus Coronary Artery Bypass Surgery: A Meta-Analysis of 1,190 Patients. Reference: Ralf E. Harskamp et al. American Heart Journal (2014), epub ahead of print. Hybrid revascularization combines long-term patency of the mammary artery connected to the left anterior descending with minimally invasive drug-eluting stents to other injuries. This in<a href="https://solaci.org/en/2014/02/18/hybrid-revascularization-versus-conventional-surgery-advantages-and-disadvantages-for-choosing-ideal-patients/" title="Read more" >...</a>
Longer follow-up registry of angioplasty in left main coronary artery. Significant differences according to the diseased segment.
Original title: The DELTA Registry (Drug-Eluting Stent for Left Main Coronary Artery Disease): A Multicenter registry Evaluating Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for left Main Treatment Reference: Naganuma T, et al. J Am Coll Cardiol Intv 2013;6:1242–9 Angioplasty of the unprotected left coronary trunk has increased significantly in recent years showing good results. Currently the<a href="https://solaci.org/en/2014/01/20/longer-follow-up-registry-of-angioplasty-in-left-main-coronary-artery-significant-differences-according-to-the-diseased-segment/" title="Read more" >...</a>
Noncardiac surgery is safe after 6 months after implantation of a DES
Original title: Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. Reference: Hawn MT et al. JAMA 2013;DOI:10.1001 In the patients who underwent non cardiac surgery and had coronary angioplasty with stent history within 2 years there was not increased in major cardiac events (MACE ) with the exception of those who were<a href="https://solaci.org/en/2013/10/11/noncardiac-surgery-is-safe-after-6-months-after-implantation-of-a-des/" title="Read more" >...</a>
Cilostazol reduces restenosis of DES in lesions larger than 40 mm.
Original title: Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the Pooled Analysis of DECLARE Trials). Reference: Seung-Whan Lee et al. Am J Cardiol 2013, article in press. Cilostazol, an inhibitor of phosphodiesterase III , associated with aspirin and clopidogrel showed decrease angiographic restenosis both in conventional stents as well as<a href="https://solaci.org/en/2013/10/07/cilostazol-reduces-restenosis-of-des-in-lesions-larger-than-40-mm/" title="Read more" >...</a>
Pharmacological stent intimal coverage with overlap versus no overlap
Original title: Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: In vivo assessment with optical coherence tomography. Reference: Juan Luis Gutiérrez-Chico et al. Am Heart J 2013;166:83-94.e3. The drug-eluting stent’s (DES) overlapping effect over neointimal healing is not completely understood. Drug overdose, large amounts of polymer and<a href="https://solaci.org/en/2013/08/05/pharmacological-stent-intimal-coverage-with-overlap-versus-no-overlap/" title="Read more" >...</a>
Hybrid revascularization, combining strengths in high-risk patients
Original title: One-Stop Hybrid Coronary Revascularization versus Coronary Artery Bypass Graft and Percutaneous Coronary Intervention for the Treatment of Multivessel Coronary Artery Disease: Three-Year Follow-up Results from A Single Institution. Reference: Liuzhong Shen et al. J Am Coll Cardiol Intv 2013. Article in press. Accepted Manuscript. A mammary bridge to anterior descending artery (LMCA) with a permeability ><a href="https://solaci.org/en/2013/05/03/hybrid-revascularization-combining-strengths-in-high-risk-patients/" title="Read more" >...</a>
Future strategies to prevent restenosis and stent thrombosis
Original title: Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification. Reference: Douglas G et al. European Heart Journal doi:10.1093/eurheartj/ehs240 Experimental models of vascular injury have shown that the rate of endothelial cell repopulation post-injury is a critical factor in determining subsequent neointima formation as well as<a href="https://solaci.org/en/2012/12/04/future-strategies-to-prevent-restenosis-and-stent-thrombosis/" title="Read more" >...</a>
Diabetics with multivessel, must keep waiting.
Original title: Strategies for Multivessel Revascularization in Patients with Diabetes. The FREEDOM Trial. Reference: Michael E. Farkouh et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1211585 This study was designed to determine the best revascularization strategy in diabetic patients with multivessel using current techniques of angioplasty (PCI) and surgery (CABG). Randomized 1:1 diabetic patients with injuries > 70%<a href="https://solaci.org/en/2012/11/08/diabetics-with-multivessel-must-keep-waiting/" title="Read more" >...</a>